Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightOnly three incidences of stent thrombosis were found at the 12-month follow-up.Conclusion: The study results showed excellent safety and clinical effectiveness of Supraflex in a high proportion of high-risk real-world Indianpatients with coronary artery disease. (Anatol J Cardiol 2020; 24: 364-9)
📌 3 Maddede Bu Makale
Özet
Objective: Supraflex (Sahajanand Medical Technologies Pvt. Ltd, Surat, India) is the latest generation of biodegradable polymer-coated sirolimus-eluting coronary stent designed on ultra-thin (60 μm) cobalt–chromium platform with flexible “S-link.” The present study was designed toestablish the safety and clinical performance of Supraflex in real-world Indian patients with coronary artery disease.Methods: The study included 839 consecutive patients with coronary artery disease who were implanted with Supraflex from January 2014 toAugust 2017 at six different tertiary care centers in India. Follow-up was performed at 30 days, 6 months, and 12 months after the index procedure.The primary end-point of the study was the incidence of major adverse cardiac events (MACE), a composite of cardiac death, myocardialinfarction (MI), and target lesion revascularization (TLR) at the 12-month follow-up. The occurrence of stent thrombosis was analyzed as safetyend-point.Results: A total of 1025 lesions were treated by implantation of 1098 Supraflex stents. At the 12-month follow-up, MACE was 4.92%, including7 (0.86%) cardiac deaths, 16 (1.97%) MI, and 17 (2.09%) TLR. Only three incidences of stent thrombosis were found at the 12-month follow-up.Conclusion: The study results showed excellent safety and clinical effectiveness of Supraflex in a high proportion of high-risk real-world Indianpatients with coronary artery disease. (Anatol J Cardiol 2020; 24: 364-9)